Compare Cenovus Energy Inc (CVE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cenovus Energy Inc trades at $31.36 (market cap $57.90B), while Regeneron Pharmaceuticals Inc trades at $741.17 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Cenovus Energy Inc pays the higher dividend (1.97%). Which is the better fit depends on your goals — on Pluang, investors hold Cenovus Energy Inc for 46 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| CVE | REGN | |
|---|---|---|
Market Cap | $57.90B | $76.14B |
Volume | 7,863,588 | 500,239 |
Sector | Energy | Health |
52-Week High | $33.92 | $852.03 |
52-Week Low | $15.85 | $557.73 |
Typical Hold Time | 46 Days | 107 Days |
Enterprise Value | $63.84B | $70.85B |
Dividend Yield | 1.97% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $31.53, up 2.94% with a bullish technical signal and strong institutional support. The stock shows solid fundamentals with a P/E of 12.43, net income margin of 11.48%, and consistent earnings beats in recent quarters. Recent analyst upgrades and positive media coverage highlight the company's attractive valuation and growth prospects in the energy sector.
Outlook remains positive with projected 2026 revenue of $58.0B and net income of $6.7B, though investors should monitor oil price volatility and execution risks. Analyst consensus leans bullish with 11 buy ratings versus 1 sell, while technical indicators suggest potential resistance near $32.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
